{"name":"Lee's Pharmaceutical Limited","slug":"lee-s-pharmaceutical-limited","ticker":"","exchange":"","domain":"leespharm.com","description":"","hq":"Beijing","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":13,"colorKey":"oncology","drugs":[{"name":"TG02 capsules oral administration, BIW in every 28d","genericName":"TG02 capsules oral administration, BIW in every 28d","slug":"tg02-capsules-oral-administration-biw-in-every-28d","indication":"Other","status":"phase_1"},{"name":"Enantone","genericName":"Enantone","slug":"enantone","indication":"Other","status":"marketed"},{"name":"intravaginal prasterone","genericName":"intravaginal prasterone","slug":"intravaginal-prasterone","indication":"Treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause","status":"phase_3"},{"name":"AU409","genericName":"AU409","slug":"au409","indication":"Other","status":"phase_1"},{"name":"Aspirine","genericName":"Aspirine","slug":"aspirine","indication":"Other","status":"marketed"},{"name":"Clindamycin Gel","genericName":"Clindamycin Gel","slug":"clindamycin-gel","indication":"Other","status":"marketed"},{"name":"Felodipine sustained-release tablet","genericName":"Felodipine sustained-release tablet","slug":"felodipine-sustained-release-tablet","indication":"Other","status":"marketed"},{"name":"Levocarnitine Injection","genericName":"Levocarnitine Injection","slug":"levocarnitine-injection","indication":"Other","status":"marketed"},{"name":"Lidocaine (Zingo)","genericName":"Lidocaine (Zingo)","slug":"lidocaine-zingo","indication":"Topical anesthesia prior to needle procedures (venipuncture, intravenous access) in pediatric and adult patients","status":"phase_3"},{"name":"Lutrate","genericName":"Lutrate","slug":"lutrate","indication":"Other","status":"marketed"},{"name":"Natulan","genericName":"Natulan","slug":"natulan","indication":"Other","status":"phase_1"},{"name":"Placebo ovules","genericName":"Placebo ovules","slug":"placebo-ovules","indication":"Clinical trial control comparator (indication-dependent on parent trial)","status":"phase_3"},{"name":"ZKAB001","genericName":"ZKAB001","slug":"zkab001","indication":"Unknown","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"Azilsartan tablets","genericName":"Azilsartan tablets","slug":"azilsartan-tablets","indication":"Hypertension","status":"phase_3"},{"name":"Olmesartan medoxomil tablets","genericName":"Olmesartan medoxomil tablets","slug":"olmesartan-medoxomil-tablets","indication":"Hypertension","status":"marketed"},{"name":"Zanidip","genericName":"Zanidip","slug":"zanidip","indication":"Hypertensive disorder","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab","genericName":"Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab","slug":"placebo-cisplatin-carboplatin-paclitaxel-bevacizumab","indication":"Advanced or metastatic solid tumors (specific indication dependent on phase 3 trial design)","status":"phase_3"},{"name":"Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab","genericName":"Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab","slug":"socazolimab-cisplatin-carboplatin-paclitaxel-bevacizumab","indication":"Non-small cell lung cancer, metastatic or locally advanced, PD-L1 positive","status":"phase_3"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Iron protein succinylate oral solution","genericName":"Iron protein succinylate oral solution","slug":"iron-protein-succinylate-oral-solution","indication":"Iron deficiency anemia","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Propionyl-L-carnitine Tablets","genericName":"Propionyl-L-carnitine Tablets","slug":"propionyl-l-carnitine-tablets","indication":"Intercritical and progressive forms of multiple sclerosis","status":"phase_3"}]}],"pipeline":[{"name":"TG02 capsules oral administration, BIW in every 28d","genericName":"TG02 capsules oral administration, BIW in every 28d","slug":"tg02-capsules-oral-administration-biw-in-every-28d","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Enantone","genericName":"Enantone","slug":"enantone","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Iron protein succinylate oral solution","genericName":"Iron protein succinylate oral solution","slug":"iron-protein-succinylate-oral-solution","phase":"marketed","mechanism":"Iron protein succinylate provides bioavailable iron in a protein-chelated form to treat iron deficiency by replenishing iron stores.","indications":["Iron deficiency anemia"],"catalyst":""},{"name":"intravaginal prasterone","genericName":"intravaginal prasterone","slug":"intravaginal-prasterone","phase":"phase_3","mechanism":"Intravaginal prasterone is a vaginal progesterone that mimics the natural hormone progesterone to treat symptoms of menopause.","indications":["Treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause"],"catalyst":""},{"name":"AU409","genericName":"AU409","slug":"au409","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Aspirine","genericName":"Aspirine","slug":"aspirine","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Azilsartan tablets","genericName":"Azilsartan tablets","slug":"azilsartan-tablets","phase":"phase_3","mechanism":"Azilsartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure.","indications":["Hypertension"],"catalyst":""},{"name":"Clindamycin Gel","genericName":"Clindamycin Gel","slug":"clindamycin-gel","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Felodipine sustained-release tablet","genericName":"Felodipine sustained-release tablet","slug":"felodipine-sustained-release-tablet","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Levocarnitine Injection","genericName":"Levocarnitine Injection","slug":"levocarnitine-injection","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lidocaine (Zingo)","genericName":"Lidocaine (Zingo)","slug":"lidocaine-zingo","phase":"phase_3","mechanism":"Lidocaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.","indications":["Topical anesthesia prior to needle procedures (venipuncture, intravenous access) in pediatric and adult patients"],"catalyst":""},{"name":"Lutrate","genericName":"Lutrate","slug":"lutrate","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Natulan","genericName":"Natulan","slug":"natulan","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Olmesartan medoxomil tablets","genericName":"Olmesartan medoxomil tablets","slug":"olmesartan-medoxomil-tablets","phase":"marketed","mechanism":"Olmesartan medoxomil blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure.","indications":["Hypertension","Reduction of cardiovascular risk in patients with hypertension"],"catalyst":""},{"name":"Placebo ovules","genericName":"Placebo ovules","slug":"placebo-ovules","phase":"phase_3","mechanism":"Placebo ovules contain inert ingredients with no active pharmaceutical component and produce therapeutic effects primarily through the placebo effect.","indications":["Clinical trial control comparator (indication-dependent on parent trial)"],"catalyst":""},{"name":"Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab","genericName":"Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab","slug":"placebo-cisplatin-carboplatin-paclitaxel-bevacizumab","phase":"phase_3","mechanism":"This combination regimen uses platinum-based chemotherapy and a taxane to damage cancer cell DNA, combined with an anti-angiogenic monoclonal antibody to block tumor blood vessel formation.","indications":["Advanced or metastatic solid tumors (specific indication dependent on phase 3 trial design)"],"catalyst":""},{"name":"Propionyl-L-carnitine Tablets","genericName":"Propionyl-L-carnitine Tablets","slug":"propionyl-l-carnitine-tablets","phase":"phase_3","mechanism":"Propionyl-L-carnitine is a carnitine derivative that may improve blood flow and reduce oxidative stress.","indications":["Intercritical and progressive forms of multiple sclerosis","Atherosclerosis","Erectile dysfunction","Intermittent claudication"],"catalyst":""},{"name":"Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab","genericName":"Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab","slug":"socazolimab-cisplatin-carboplatin-paclitaxel-bevacizumab","phase":"phase_3","mechanism":"Socazolimab is a PD-1 inhibitor monoclonal antibody, while Bevacizumab is a VEGF inhibitor monoclonal antibody. Paclitaxel is a microtubule inhibitor, and cisplatin/carboplatin are platinum-based DNA crosslinking agents.","indications":["Non-small cell lung cancer, metastatic or locally advanced, PD-L1 positive","Other cancers with PD-L1 expression"],"catalyst":""},{"name":"ZKAB001","genericName":"ZKAB001","slug":"zkab001","phase":"phase_3","mechanism":"ZKAB001 is a small molecule drug that targets the molecular target.","indications":["Unknown"],"catalyst":""},{"name":"Zanidip","genericName":"Zanidip","slug":"zanidip","phase":"marketed","mechanism":"Voltage-gated L-type calcium channel","indications":["Hypertensive disorder"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPLUR5UTR6cUZBMVZPYnYzRWNOXy1WVWlnZFF2UGhEQzY4VXdzeE5EZE0tVm9lY09WYktZUTVaNEJCME1KelhibUZRemhZc0FYcE5rOVVwUXpBN2JZOEZFRS1zajJNRDN5ZG9CR2FEeE9MNUsxUkxfaDVYNEYzem9mdjU5aG1rRlFObUpJRUNocHBrYXZ3aFBKX09UNlkzRjJqb2dVdEV5VmRrN18wVm5aZi1MMmZ4cjRG?oc=5","date":"2026-03-31","type":"pipeline","source":"Markets Mojo","summary":"Gan & Lee Pharmaceuticals Hits Day High with Strong 5.34% Surge - Markets Mojo","headline":"Gan & Lee Pharmaceuticals Hits Day High with Strong 5.34% Surge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxOMzNmSzFJRS1CU20tQ2xKMzBxeEtLOGlIQmQ3TXQ5UlVSTl93SmZvZzlIZ3lONlN1ZzkteUduYUFhTVpiemkzREVzZU4wZU9oWFpiOThrMkNnNy1ybjZVVTl1bVhYUFJESWZ4cW9fSURtaEJDaE1YRVNOYmE1VzNnbDEyX1FNNEFPMGZoZmhoWE01SnF0QW40ZklnblZJTXJSbXM3MXRBQzVtWjRwbFRtZ2RhZGd4WWo1VTBuLV8zcFp5T1d5dlZEaXRRUWpUNmd1Tl9CMHdLanR6Q0hCMFJHcnVreHJEbFM3?oc=5","date":"2026-03-26","type":"regulatory","source":"Minichart","summary":"Lee’s Pharmaceutical Receives NMPA Approval for Intrarosa to Treat Vulvovaginal Atrophy in Postmenopausal Women 1 - Minichart","headline":"Lee’s Pharmaceutical Receives NMPA Approval for Intrarosa to Treat Vulvovaginal Atrophy in Postmenopausal Women 1","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxNN3VGNU0tVml2SV90SDQxTnh0RFZXay1oYkR1d3hveEltYVBKTzl3cC1vWGF6RUdhTFRIX3lFQXNETXFZaURSdG9BcHRHUkpndXBtd2FWc0s0RlN6ZE55SG85OGVCOFVaNmhwSmF2dWNyY1liUGhlS3RTQWItS2h3a1JTRVNIY3VOMTM3blBVV0Z3S3lrZUp4WkZaM3JaSEFCcWVTYm8wcGpfU0REOUJYUkxDenhvMUVMUDJtVVZRd2RpR1JELTZFbEVrZw?oc=5","date":"2026-03-25","type":"regulatory","source":"TipRanks","summary":"Lee’s Pharm Wins China Approval for Intrarosa, Bolstering Women’s Health Portfolio - TipRanks","headline":"Lee’s Pharm Wins China Approval for Intrarosa, Bolstering Women’s Health Portfolio","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUkQ5Sjg1VDNmQnNuMkdvdVpId3dSYjNYX1BPN3l2SWNJNVJuM1RMZU9uVTFYN0FvZ3FqQW1pU1ZmRWpLUndUVWNJQVF1eWpIaVZ4ZVVQWU1rVktrLWNaNFVLRGVpaWhILXkyN2xCeUVBaFNfOXk0OEg0ZGhEYkwwSWtrTFJCMkRwaXlsYmxGNHRrRkZIUERVcEE5RXc0ZVpaVmF4dmVXb0tLZw?oc=5","date":"2026-01-15","type":"pipeline","source":"BioWorld News","summary":"Gan & Lee Pharmaceuticals discloses new ER-α degradation inducers - BioWorld News","headline":"Gan & Lee Pharmaceuticals discloses new ER-α degradation inducers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNcTB4YW1Rek9DQmUwWFZDc3B2b2FsOGs4SnE5YWhFdWpIUENXTUtoVG5WbGhtZURINk1iYVUySXptRVFzZFJicEM4eG82eHZvZW1OQmJ2eW5ZZUU0ZEYySnhpbERHTExoZzlTc0phVm1tdzBLYkdxRFhQdnhkektjZ1AtUW5kRGFjMXZ1SFQzZzFURWNzZkN2MVVMdUd2U294T0xkdjZR?oc=5","date":"2025-12-31","type":"deal","source":"The Pharma Letter","summary":"Lupin signs exclusive GLP-1 licensing deal with Gan & Lee - The Pharma Letter","headline":"Lupin signs exclusive GLP-1 licensing deal with Gan & Lee","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-30","type":"deal","source":"ET Pharma","summary":"Lupin in-licenses fortnightly weight-loss drug from China’s Gan & Lee Pharma - ET Pharma","headline":"Lupin in-licenses fortnightly weight-loss drug from China’s Gan & Lee Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxQUFBEcF9WNkRibEVHMWdqSHNZajViNWdCUXU1U3hQTk9QMG5aLTlfUVNjVzcxcVBuX2N2ZllBcGZfRzlHa2VzUmE3S0NGX196SkNQMXRzcTE5aVI0Y0xIWHFIYTVWNkNBdWRkR2dKajgzcGJrVE54UGg1YUJKV0RoTmZBSW5saFl6Znd3M01Cb1BFT1BucTdRQ3Q1Y29nYzFHcXc2aDJvRkRfdGVXOUZYc1NDMjFiZkxxNWQyV2d6NHIxLUJuQl9pR0xmNnR1SlJiOHZWd2YxQjExLTQ?oc=5","date":"2025-12-30","type":"pipeline","source":"Dalal Street Investment Journal","summary":"Global Pharma Major-Lupin Signs Agreement with Gan & Lee Pharmaceuticals for Novel GLP-1 Receptor Agonist - Dalal Street Investment Journal","headline":"Global Pharma Major-Lupin Signs Agreement with Gan & Lee Pharmaceuticals for Novel GLP-1 Receptor Agonist","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-30","type":"pipeline","source":"The Economic Times","summary":"Lupin shares in focus after licensing pact with China’s Gan & Lee for GLP-1 drug - The Economic Times","headline":"Lupin shares in focus after licensing pact with China’s Gan & Lee for GLP-1 drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxQVHdjS0tYY3MyT29XaWRNYjMtVTJGbDkwVmVycmx6VGh4Y3Y2cEZOTTdON180RlFzeU1jckZRQl9PcnR4QTlnbzcxbG5jVG9nUWxjZkRYaFJydkxzRmZKU0FTTHhFdVhCTlNWNmgyYjhtWExKb2huczBJZUQtSjlXVklIZDJ0eHZDam80MGhtMzZfVkMzZ3JiNHVvR0NsNlJqQjdqaTJSLV93OFNnUmt6VTNEZDZRZ0tvLThfMjM4YzVVYUFhTDNGcDVUQjBUc2ZJRWZ5ZXRYWUVpV0hqWFZJ?oc=5","date":"2025-12-29","type":"pipeline","source":"lupin.com","summary":"Lupin Signs Exclusive Licensing Agreement with Gan & Lee Pharmaceuticals for novel GLP-1 receptor agonist - lupin.com","headline":"Lupin Signs Exclusive Licensing Agreement with Gan & Lee Pharmaceuticals for novel GLP-1 receptor agonist","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wJBVV95cUxNcEd6Rkt1MDFqcjhKb3lGcFJKT0dKOUFfcS1aOUtKTEtXMzB0Mzd3dGF1NGRlTExhMGQ4dGFVMEhFaDhLZ1RiSEpMb0VqWGZtVmFXM1ZQUHF2cnQ0UEVkT0ExeEticlFxaTA5NDZYY1BWQ3B5cWJPU2hsWjBwZGthR0plc18wNUhJNzA5enpJOTRTUURWV3pvclpwbVdJcnMxR0x4WVdmY21MQktTYTdDdFBWYmxqMkR0T2RFNEotZGc4SUxGNG9PNVRIblpvTWJJSjNGTU1xX1BQT0YxeFRSNENReGpUeTR1WDZLZm1EN2MxM2JrYlJXeHUzU3BQSFV6MVBrSEZ3MnhYLUNFVXlSLUxsUG0wMWlnVDdmcC14YUVMNjZFMmhpUWMzUjlwYWJxbTVuSF9qX215VnFPdGNpUjZHTll3MTI1UTBVNHAyVkQ0WXVpRHdnVS1tVGtUbndRU0NF?oc=5","date":"2025-12-11","type":"deal","source":"PR Newswire","summary":"Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights - PR N","headline":"Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Ex","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgJBVV95cUxOcktDZWtzMlBoNUNLNWVvMmJ4YlNOMGpZZlN6WjFycGtfT3JmbUZXbkx4UEZWQkRZME1KZDZmemJqOElOUkpsWDlsWXFsTW1PbHVHNks4QkQwVi00VExUNjFLaFhLWlpNWEt4WDQyR0h4SDhTNkVHc3Bta3p3bWxZOUxIZXFmR2R5SG9XaE4xa1h3ZnZFSV9BZU9FYkdWLVkxNlBzY19FS21CbUR4UnZXeTZ4M0dzOXZlTFVNSUxONWljbGY1T0puMnZLR0RnRXY0cU9obWExX1A3R1RtZlJnV0xycm5YbDFNMUJNSmQ0Qk0xNGpNN3k3bVNsSFRUeGNkR3YxRERzUnVJdEs3N3psTkxEZEdpVzhIanlwZ1o3UTh2TC14S0I5aDlYdFd0TXRxS1FhZHpB?oc=5","date":"2025-11-27","type":"trial","source":"PR Newswire","summary":"Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management - PR Newswire","headline":"Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxQNjI5aFkwV25rcDQxdktxbHppUmh4QVZrOWdtMXZtRmZwR01nZDFuNDI0NkNLdTVyRmZ3Wm9jOGxIaHkteDhWV1dpaWM4M053SE0yWnRxbVRYWWFwWWc3djFmUFdWRFhaTU9XUzNFcjA0aDJHSzljXzEyTzZFNzNXc1F2eDRXOEpKSDRiREF5eEJUbEhVSnRYV3pjY19jeUxSR3I5MlpsckttRTF4TGxYYlBQcWlyemc3V0Q1RTJBeDExRDA1Zk9wQ3JCVGtsbzd3akZVUzVqdmwxSml2SFZYV2Z1ZlJWdXNwT0FaZklHQS1BTUtNRHVmRFBvcjZBYXk1ZHV5NG9wSVBlSE56RXgyYnZyelRGbmp0YmU3aExjY3dwbTVF?oc=5","date":"2025-06-21","type":"pipeline","source":"PR Newswire","summary":"Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions - PR Newswire","headline":"Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's ","sentiment":"neutral"}],"patents":[],"drugCount":20,"phaseCounts":{"phase_1":3,"marketed":9,"phase_3":8},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}